Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Linezolid Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02066402
View directory record Official record
Conditions
Bacterial Infections
Interventions
Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

NCT00948142
View directory record Official record
Conditions
Skin Diseases, Bacterial
Interventions
CEM-102, Linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

NCT03032380
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Meropenem, Linezolid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01421511
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FA, Linezolid
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

NCT02378480
View directory record Official record
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Sep 10, 2026, 5:52 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

NCT00359632
View directory record Official record
Conditions
Optic Nerve Diseases
Interventions
Zyvox - linezolid, Matched control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jonesboro, Arkansas • West Palm Beach, Florida • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

NCT00396084
View directory record Official record
Conditions
Tuberculosis
Interventions
Gatifloxacin, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 10, 2026, 5:52 AM EDT
Terminated Not applicable Interventional Results available

Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections

NCT01619410
View directory record Official record
Conditions
Skin Diseases, Bacterial, Abscess
Interventions
Linezolid, Clindamycin
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 10, 2026, 5:52 AM EDT
Withdrawn Phase 3 Interventional

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

NCT02269644
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Dalbavancin, Linezolid, Linezolid Placebo, Azithromycin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

NCT01283581
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Linezolid, Vancomycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

NCT02559310
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00084266
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid (Zyvox), vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
108
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

NCT02877927
View directory record Official record
Conditions
Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
Omadacycline, Linezolid
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

NCT01128530
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 4 Interventional Results available

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

NCT00087490
View directory record Official record
Conditions
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,077 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
76
States / cities
Montgomery, Alabama • Tucson, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01339091
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Vancomycin / Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
55
States / cities
Anaheim, California • Azusa, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males

NCT01544673
View directory record Official record
Conditions
Gram Positive Infection
Interventions
linezolid, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 10, 2026, 5:52 AM EDT
Not listed No phase listed Observational

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

NCT06126263
View directory record Official record
Conditions
Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream, Infection, Bacterial, Streptococcal Toxic Shock Syndrome
Interventions
Linezolid, Clindamycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT03747497
View directory record Official record
Conditions
Skin Diseases, Bacterial, Gram-Positive Bacterial Infections
Interventions
contezolid acefosamil, linezolid 600 mg
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Chula Vista, California • La Mesa, California • Long Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 10, 2026, 5:52 AM EDT
Completed Phase 3 Interventional Results available

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

NCT01170221
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FA, Linezolid
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Dothan, Alabama • Anaheim, California • Buena Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 10, 2026, 5:52 AM EDT